<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578382</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-NR2010-0433/0</org_study_id>
    <nct_id>NCT01578382</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)</brief_title>
  <official_title>Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU): A Comparison of Martorell HYTILU, Calciphylaxis and Venous Ulcer (Control)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Martorell hypertensive ischemic leg ulcer is a severe type of skin necrosis (skin infarction)
      which occurs in long-term hypertensive subjects.

      Calciphylaxis (calcific uremic arteriolopathy) is a severe type of skin necrosis (skin
      infarction) which occurs in subjects with end-stage kidney disease or after kidney
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative study including

        -  20 consecutive patients with Martorell HYTILU

        -  10 consecutive patients with Calciphylaxis (calcific uremic arteriolopathy)

        -  20 patients with venous ulcer

      The following parameters are measured in the blood serum:

      White blood count; c-reactive protein; creatinine; calcium (total); free (ionized) calcium;
      phosphate; albumin; 25-hydroxyvitamin-D; 1-25-dihydroxyvitamin-D; homocysteine; cystatin C
      alphafetoin, osteoprotegerin; fibroblast growth factor 23 (FGF-23); globular arrest 1 (GLA-1)

      The following parameters are measured in samples of diseased (necrobiotic) skin:

      alphafetoin, osteoprotegerin; fibroblast growth factor 23 (FGF-23); globular arrest 1 (GLA-1)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Martorell HYTILU and calciphylaxis show both decreased tissue protection mechanisms against tissue calcification</measure>
    <time_frame>36 months</time_frame>
    <description>Comparison of the calcification-protective factors GLA-1(serum protein alpha2-Heremans-Schmid glycoprotein/fetuin A), Osteoprotegerin, Fibroblast Growth Factor 23, and Alphafetoin in:
Martorell HYTILU (A1)
Calciphylaxis (calcific uremic arteriolopathy)(A2)
Venous ulcers (as control group)(B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Martorell hypertensive ischemic leg ulcer and calciphylaxis are both characterized by non-infectious inflammation</measure>
    <time_frame>36 months</time_frame>
    <description>Comparison of C-reactive protein, procalcitonin and white blood cell count in:
Martorell HYTILU (A1)
Calciphylaxis (calcfic uremic arteriolopathy) (A2)
Venous ulcers (control group) (B)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertensive Ischemic Leg Ulcer</condition>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>Hypertensive ischemic leg ulcer</arm_group_label>
    <description>Twenty consecutive patients with Martorell HYTILU as defined in:
Arch Dermatol 2010;146:961-968</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calciphylaxis</arm_group_label>
    <description>Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:
Vasa 1998;27:137-143</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous ulcer (controls)</arm_group_label>
    <description>Twenty subjects with venous ulcers (CEAP C4-6) as described in:
J Vasc Surg. 2004 Dec;40(6):1248-52</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum (2 tubes); blood plasma in citrate (2 tubes); blood plasma in heparin (2 tubes)
      Diseased skin tissue in formalin for paraffin embedded H-E histology; Diseased skin tissue
      snap frozen Diseased skin tissue in &quot;RNA later&quot; tube (1 tube)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        n=20: Having Martorell hypertensive ischemic leg ulcer (as defined above) or n=10: Having
        Calciphylaxis (calcific uremic arteriolopathy (as defined above) or n=20: Having a venous
        ulcer (as defined above) (controls)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having Martorell hypertensive ischemic leg ulcer (as defined above) or

          -  Having Calciphylaxis (calcific uremic arteriolopathy (as defined above) or

          -  Having a venous ulcer (as defined above)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J端rg Hafner, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospital of Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J端rg Hafner, Prof. MD</last_name>
    <phone>+41 44 255 25 33</phone>
    <email>juerg.hafner@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars E French, Prof. MD</last_name>
    <phone>+41 44 255 25 50</phone>
    <email>lars.french@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J端rg Hafner, Prof. MD</last_name>
      <phone>+41 44 255 25 33</phone>
      <email>juerg.hafner@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Lars E French, Prof. MD</last_name>
      <phone>+41 44 255 25 50</phone>
      <email>lars.french@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>J端rg Hafner, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Martorell hypertensive ischemic leg ulcer</keyword>
  <keyword>Calciphylaxis (calcific uremic arteriolopathy)</keyword>
  <keyword>Ischemic subcutaneous arteriolosclerosis</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Medial calcinosis</keyword>
  <keyword>Wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Calciphylaxis</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

